Compare Lupin with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs ALKEM LABORATORIES - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN ALKEM LABORATORIES LUPIN/
ALKEM LABORATORIES
 
P/E (TTM) x 41.2 22.1 186.7% View Chart
P/BV x 3.8 5.3 71.2% View Chart
Dividend Yield % 0.6 0.9 62.7%  

Financials

 LUPIN   ALKEM LABORATORIES
EQUITY SHARE DATA
    LUPIN
Mar-20
ALKEM LABORATORIES
Mar-20
LUPIN/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8822,720 32.4%   
Low Rs5051,660 30.4%   
Sales per share (Unadj.) Rs339.4697.9 48.6%  
Earnings per share (Unadj.) Rs-5.996.1 -6.2%  
Cash flow per share (Unadj.) Rs15.5117.3 13.2%  
Dividends per share (Unadj.) Rs6.0025.00 24.0%  
Dividend yield (eoy) %0.91.1 75.8%  
Book value per share (Unadj.) Rs276.7515.2 53.7%  
Shares outstanding (eoy) m453.00119.57 378.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.03.1 65.1%   
Avg P/E ratio x-116.622.8 -511.9%  
P/CF ratio (eoy) x44.818.7 240.0%  
Price / Book Value ratio x2.54.3 59.0%  
Dividend payout %-100.926.0 -387.9%   
Avg Mkt Cap Rs m314,201261,879 120.0%   
No. of employees `00018.314.3 127.7%   
Total wages/salary Rs m29,86815,055 198.4%   
Avg. sales/employee Rs Th8,400.65,822.6 144.3%   
Avg. wages/employee Rs Th1,632.01,050.5 155.4%   
Avg. net profit/employee Rs Th-147.2802.0 -18.4%   
INCOME DATA
Net Sales Rs m153,74883,444 184.3%  
Other income Rs m4,8381,042 464.2%   
Total revenues Rs m158,58584,486 187.7%   
Gross profit Rs m24,84914,734 168.7%  
Depreciation Rs m9,7022,528 383.9%   
Interest Rs m3,630651 557.9%   
Profit before tax Rs m16,35512,598 129.8%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,5711,105 1,047.3%   
Profit after tax Rs m-2,69411,493 -23.4%  
Gross profit margin %16.217.7 91.5%  
Effective tax rate %70.88.8 806.8%   
Net profit margin %-1.813.8 -12.7%  
BALANCE SHEET DATA
Current assets Rs m154,13254,960 280.4%   
Current liabilities Rs m92,25232,433 284.4%   
Net working cap to sales %40.227.0 149.1%  
Current ratio x1.71.7 98.6%  
Inventory Days Days8280 103.2%  
Debtors Days Days12972 179.2%  
Net fixed assets Rs m89,08232,710 272.3%   
Share capital Rs m906239 378.9%   
"Free" reserves Rs m124,46161,368 202.8%   
Net worth Rs m125,36761,607 203.5%   
Long term debt Rs m17,9331,592 1,126.1%   
Total assets Rs m249,83999,433 251.3%  
Interest coverage x5.520.4 27.0%   
Debt to equity ratio x0.10 553.4%  
Sales to assets ratio x0.60.8 73.3%   
Return on assets %0.412.2 3.1%  
Return on equity %-2.118.7 -11.5%  
Return on capital %8.721.0 41.6%  
Exports to sales %019.1 0.0%   
Imports to sales %03.0 0.0%   
Exports (fob) Rs mNA15,917 0.0%   
Imports (cif) Rs mNA2,483 0.0%   
Fx inflow Rs m51,45016,061 320.3%   
Fx outflow Rs m19,4702,483 784.2%   
Net fx Rs m31,98013,578 235.5%   
CASH FLOW
From Operations Rs m14,6885,851 251.0%  
From Investments Rs m11,070-7,414 -149.3%  
From Financial Activity Rs m-8,906792 -1,125.2%  
Net Cashflow Rs m16,853-731 -2,305.1%  

Share Holding

Indian Promoters % 46.6 66.9 69.7%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 33.1 34.1%  
FIIs % 31.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 0.0 -  
Shareholders   98,259 68,381 143.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   GLENMARK PHARMA  FULFORD INDIA  ORCHID PHARMA  AJANTA PHARMA  UNICHEM LAB  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Dives Over 1,100 Points, Dow Futures Down by 119 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 1,148 points, down 2.4% at 47,683 levels.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Apr 19, 2021 02:28 PM

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS